Zevtaxel contains Cabazitaxel, an anti-cancer medication belonging to the taxane class. It is primarily used in combination with prednisone or prednisolone to treat metastatic castration-resistant prostate cancer (mCRPC) that has progressed despite prior chemotherapy, including treatments with docetaxel. Zevtaxel(Cabazitaxel) is a vital therapeutic option for patients with advanced prostate cancer resistant to prior treatments. Its efficacy in extending survival must be balanced with its side effect profile, necessitating careful patient selection, premedication, and monitoring to optimize outcomes.

Indications- Metastatic Castration-Resistant Prostate Cancer (mCRPC): In combination with prednisone or prednisolone, it is used for patients whose disease has progressed after docetaxel-based therapy.

Cabazitaxel disrupts the microtubular network essential for mitotic and interphase cellular functions. By binding to tubulin, it promotes the assembly of microtubules while inhibiting their disassembly, leading to the inhibition of cell division and cancer cell proliferation.